Precision BioSciences (NASDAQ:DTIL – Get Free Report) and Revolution Medicines (NASDAQ:RVMD – Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.
Profitability
This table compares Precision BioSciences and Revolution Medicines’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Precision BioSciences | -125.84% | -204.66% | -35.19% |
| Revolution Medicines | N/A | -38.39% | -33.61% |
Valuation and Earnings
This table compares Precision BioSciences and Revolution Medicines’ gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Precision BioSciences | $48.73 million | 1.55 | -$61.32 million | ($16.07) | -0.68 |
| Revolution Medicines | $11.58 million | 551.37 | -$436.37 million | ($3.77) | -9.93 |
Risk and Volatility
Precision BioSciences has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500. Comparatively, Revolution Medicines has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Precision BioSciences and Revolution Medicines, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Precision BioSciences | 0 | 0 | 3 | 0 | 3.00 |
| Revolution Medicines | 0 | 0 | 9 | 1 | 3.10 |
Precision BioSciences presently has a consensus target price of $46.33, indicating a potential upside of 323.91%. Revolution Medicines has a consensus target price of $41.60, indicating a potential upside of 11.08%. Given Precision BioSciences’ higher possible upside, analysts plainly believe Precision BioSciences is more favorable than Revolution Medicines.
Insider & Institutional Ownership
38.0% of Precision BioSciences shares are owned by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are owned by institutional investors. 5.1% of Precision BioSciences shares are owned by company insiders. Comparatively, 8.5% of Revolution Medicines shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Revolution Medicines beats Precision BioSciences on 10 of the 15 factors compared between the two stocks.
About Precision BioSciences
Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
About Revolution Medicines
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Receive News & Ratings for Precision BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.
